Imported leishmaniasis in travelers: a 7-year retrospective from a Parisian hospital in France.
Cutaneous leishmaniasis
Cytochrome b sequencing
Leishmania infantum
Leishmania major
Leishmania tropica
Quantitative PCR
Visceral leishmaniasis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Sep 2021
15 Sep 2021
Historique:
received:
10
05
2021
accepted:
19
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Leishmaniases are regularly seen in non-endemic areas due to the increase of international travels. They include cutaneous leishmaniases (CL) and mucocutaneous (MC) caused by different Leishmania species, and visceral leishmaniases (VL) which present with non-specific symptoms. We reviewed all consecutive leishmaniasis cases seen between September 2012 and May 2020. The diagnostic strategy included microscopy after May-Grünwald-Giemsa staining, a diagnostic quantitative PCR (qPCR) assay, and species identification based on sequencing of the cytochrome b gene. Eighty-nine patients had a definitive leishmaniasis diagnosis. Nine patients had VL with Leishmania infantum. Eighty patients had CL. Twelve patients acquired CL after trips in Latin America (7 Leishmania guyanensis, 2 Leishmania braziliensis, 2 Leishmania mexicana, and 1 Leishmania panamensis). Species could be identified in 63 of the 68 CLs mainly after travel in North Africa (59%) with Leishmania major (65%), Leishmania tropica/killicki (24%), and L. infantum (11%), or in West Sub-Saharan Africa (32%), all due to L. major. The median day between appearance of the lesions and diagnosis was 90 [range 60-127]. Our diagnostic strategy allows both positive diagnoses and species identifications. Travelers in West Sub-Saharan Africa and North Africa should be better aware of the risk of contracting leishmananiasis.
Sections du résumé
BACKGROUND
BACKGROUND
Leishmaniases are regularly seen in non-endemic areas due to the increase of international travels. They include cutaneous leishmaniases (CL) and mucocutaneous (MC) caused by different Leishmania species, and visceral leishmaniases (VL) which present with non-specific symptoms.
METHODS
METHODS
We reviewed all consecutive leishmaniasis cases seen between September 2012 and May 2020. The diagnostic strategy included microscopy after May-Grünwald-Giemsa staining, a diagnostic quantitative PCR (qPCR) assay, and species identification based on sequencing of the cytochrome b gene.
RESULTS
RESULTS
Eighty-nine patients had a definitive leishmaniasis diagnosis. Nine patients had VL with Leishmania infantum. Eighty patients had CL. Twelve patients acquired CL after trips in Latin America (7 Leishmania guyanensis, 2 Leishmania braziliensis, 2 Leishmania mexicana, and 1 Leishmania panamensis). Species could be identified in 63 of the 68 CLs mainly after travel in North Africa (59%) with Leishmania major (65%), Leishmania tropica/killicki (24%), and L. infantum (11%), or in West Sub-Saharan Africa (32%), all due to L. major. The median day between appearance of the lesions and diagnosis was 90 [range 60-127].
CONCLUSIONS
CONCLUSIONS
Our diagnostic strategy allows both positive diagnoses and species identifications. Travelers in West Sub-Saharan Africa and North Africa should be better aware of the risk of contracting leishmananiasis.
Identifiants
pubmed: 34525963
doi: 10.1186/s12879-021-06631-5
pii: 10.1186/s12879-021-06631-5
pmc: PMC8442464
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
953Informations de copyright
© 2021. The Author(s).
Références
Cell Microbiol. 2008 Jun;10(6):1221-34
pubmed: 18363880
Infect Dis Poverty. 2018 Apr 12;7(1):32
pubmed: 29642944
Clin Chim Acta. 2006 Jan;363(1-2):221-8
pubmed: 16102739
PLoS Negl Trop Dis. 2014 May 01;8(5):e2832
pubmed: 24787001
Lancet Infect Dis. 2008 Mar;8(3):191-9
pubmed: 18291340
PLoS Negl Trop Dis. 2020 Jan 21;14(1):e0007981
pubmed: 31961871
PLoS One. 2011 Apr 29;6(4):e19304
pubmed: 21559398
Travel Med Infect Dis. 2014 Nov-Dec;12(6 Pt A):563-81
pubmed: 25287721
Ann Parasitol. 2020;66(2):251-254
pubmed: 32592548
J Travel Med. 2014 Mar-Apr;21(2):116-29
pubmed: 24745041
J Clin Microbiol. 2007 Jul;45(7):2110-5
pubmed: 17475750
Br J Dermatol. 2019 Dec;181(6):1337-1339
pubmed: 31260088
Parasite. 2014;21:14
pubmed: 24626301
PLoS Negl Trop Dis. 2016 Nov 29;10(11):e0005141
pubmed: 27898671
Int J Environ Res Public Health. 2018 Jul 20;15(7):
pubmed: 30037049
J Travel Med. 2019 Dec 23;26(8):
pubmed: 31553455
Elife. 2014 Jun 27;3:
pubmed: 24972829
Parasit Vectors. 2014 Sep 04;7:420
pubmed: 25189460
PLoS One. 2015 Apr 01;10(4):e0121418
pubmed: 25831056
Am J Trop Med Hyg. 2010 Nov;83(5):1034-9
pubmed: 21036833
Am J Trop Med Hyg. 2016 Mar;94(3):489-93
pubmed: 26787156
Acta Trop. 2012 Jun;122(3):276-83
pubmed: 22306359
Parasit Vectors. 2019 Jul 24;12(1):359
pubmed: 31340851
Euro Surveill. 2013 Jul 18;18(29):20534
pubmed: 23929121
Med Mycol. 2015 Apr;53(3):241-7
pubmed: 25550391
Parasitology. 2004 May;128(Pt 5):483-91
pubmed: 15180316
Ann Rheum Dis. 2011 Apr;70(4):616-23
pubmed: 21177290
BMC Infect Dis. 2020 Dec 9;20(1):938
pubmed: 33297972
J Infect Chemother. 2018 Dec;24(12):990-994
pubmed: 30098915
Trop Med Int Health. 2009 Sep;14(9):1071-85
pubmed: 19624480
Rev Inst Med Trop Sao Paulo. 2020;62:e28
pubmed: 32401957
Lancet Infect Dis. 2017 Mar;17(3):264
pubmed: 28244391
Am J Trop Med Hyg. 2017 Jan 11;96(1):24-45
pubmed: 27927991
Exp Parasitol. 2019 Dec;207:107773
pubmed: 31605671
Front Pediatr. 2015 Jun 29;3:59
pubmed: 26176005
Lancet. 2018 Sep 15;392(10151):951-970
pubmed: 30126638
Int J Infect Dis. 2010 Dec;14(12):e1032-9
pubmed: 20952234
PLoS Negl Trop Dis. 2016 Jun 28;10(6):e0004811
pubmed: 27352043
Acta Trop. 2019 Sep;197:104855
pubmed: 30529443
PLoS Negl Trop Dis. 2018 Oct 25;12(10):e0006914
pubmed: 30359376